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Abstract
Background—Limited data exist regarding the neonatal and neurodevelopmental outcomes of 
infants exposed to marijuana (MJ) in-utero, particularly among preterm infants. We hypothesized 
that MJ-exposed preterm infants would have worse neonatal and childhood developmental 
outcomes compared to MJ-unexposed infants.
Methods—Secondary analysis of multicenter randomized-controlled trial of antenatal 
magnesium sulfate for prevention of cerebral palsy was conducted. Singleton non-anomalous 
infants delivered <35 weeks exposed to MJ in-utero were compared to MJ-unexposed. Primary 
neonatal outcome was death, grade 3/4 intraventricular hemorrhage, periventricular leukomalacia, 
bronchopulmonary dysplasia, and/or stage II/III necrotizing enterocolitis before discharge. 
Primary childhood outcome was death, moderate/severe cerebral palsy, or/and Bayley II Scales 
<70 at age 2. Backwards-stepwise regression used to estimate odds of primary outcomes.
Results—1,867 infants met inclusion criteria; 135(7.2%) were MJ-exposed. There were no 
differences in neonatal (20%vs26%, p=0.14) or childhood (26%vs21%, p=0.21) outcomes in MJ-
exposed infants compared to MJ-unexposed infants. In adjusted models, MJ-exposure was not 
associated with adverse neonatal outcomes (aOR 0.83 95%CI 0.47,1.44) or early childhood 
outcomes (aOR 1.47, 95%CI 0.97, 2.23).
Conclusions—Among infants born <35 weeks of gestation, MJ-exposure was not associated 
with adverse neonatal or childhood outcomes. Long-term follow up studies are needed to assess 
later childhood neurodevelopmental outcomes following MJ-exposure.
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Introduction
Marijuana (MJ) is one of the most commonly used recreational substances in the United 
States,(1) and use is currently on the rise particularly among young Hispanic and Black 
women.(2, 3) Recent studies estimate that more than 10% of pregnant women use MJ during 
pregnancy.(4) Among pregnant teenage women (15–17 years), MJ use may be as high as 
17–29%.(5, 6)
Although the prevalence of MJ among pregnant women is high, there is limited information 
on the effects of MJ use on pregnancy and neonatal outcomes. MJ use in pregnancy and its 
association with adverse neonatal outcomes including lower Apgar scores, low birth weight 
in term infants and NICU admission in term infants is conflicting.(7–10) Results of these 
studies are difficult to interpret given the high frequency of associated tobacco and drug use 
and confounding by race and age of mothers. MJ-exposure in-utero may have 
neurodevelopmental implications, including an increase in behavioral problems, poor 
performance on visual tasks, and decreased language comprehension above the age of 4 
among a cohort of babies born at term.(11, 12) However, follow-up of this same cohort of 
children between ages 9–12 showed a resolution of these differences.(13) Another large 
cohort suggested differences in verbal reasoning at age 6 in children exposed in the first 
trimester.(14) Studies of perinatal outcomes and MJ use in pregnancy are challenging given 
the multiple confounding aspects, however these reports of potential long term effects of in-
utero MJ-exposure are concerning.(15)
Since it is highly lipophilic, MJ may remain in adipose and other tissue for a prolonged 
period after a single exposure; delta 9 tetrahydrocannabinol (THC) readily crosses the 
placenta.(16) Theoretically, even single or intermittent exposures continue to affect the fetus 
long after initial exposure. Cannabinoid receptors are present in the fetal brain and the 
uterine decidua, and binding to these receptors may have undesired downstream effects. 
Effects of the increased carbon monoxide related to MJ inhalation on the fetus are unknown. 
Furthermore, both short- and long-term effects of MJ-exposure may be more pronounced in 
infants born prematurely, due to an increased susceptibility of their immature organ systems 
to perturbations.
The objective of this study was to investigate if prenatal MJ-exposure is associated with 
adverse neonatal and early childhood outcomes among preterm infants delivered <35 weeks 
gestation.
Materials / subjects, and Methods
This study is a secondary analysis of the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects 
of Antenatal Magnesium Sulfate (BEAM) randomized placebo-controlled, double-masked 
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multicenter trial of antenatal magnesium sulfate for the prevention of cerebral palsy. In this 
study, women at risk of imminent delivery between 23 5/7 and 31 6/7 weeks were recruited 
from 20 centers between 1997 and 2004, and randomized to receive placebo or magnesium. 
The details of this study were previously published.(17) This study was reviewed and 
deemed exempt from oversight by the University of North Carolina at Chapel Hill 
Institutional Review Board. We included singleton, non-anomalous live born infants who 
delivered <35 weeks and 0 days gestation. The gestational age of 35 weeks was selected in 
order to minimize exclusion of women with PPROM who were induced starting at 34 weeks 
as the majority of the study population was women with PPROM. From the original BEAM 
cohort (n=2,444), we excluded twin gestations (n=406), infants with major congenital 
anomalies (n=65) and those infants who delivered after 34 weeks and 6 days of gestation 
(n=106), leaving 1,867 infants for the analysis. Our primary exposure was prenatal MJ use. 
We used the same definition for MJ-exposure as was used in the original trial which 
included self-reported use at study enrollment or a positive drug screening test for delta-9-
tetrahydrocannabinol (THC). There are issues with self-reporting (i.e. under reporting, recall 
bias, etc). The primary neonatal outcome of this study was a composite neonatal morbidity 
including one or more of the following prior to initial hospital discharge: death prior to 
hospital discharge, grade 3 or 4 intraventricular hemorrhage (IVH), periventricular 
leukomalacia (PVL), bronchopulmonary dysplasia (BPD), and grade II or III necrotizing 
enterocolitis. The primary childhood outcome was a composite of adverse childhood 
morbidity including one or more of the following: death before age 2, moderate or severe 
cerebral palsy (CP), or a Bayley Scales of Infant Development II Mental or Psychomotor 
Developmental Indices (MDI and PDI respectively) <70 (2 standard deviations below the 
mean) assessed at age 2. CP diagnosis was made by a board-certified pediatrician or 
pediatric neurologist blinded to the treatment allocation of magnesium. All infants included 
in the analysis of the primary study were evaluated (for CP, and given a Bayley Scales of 
Infant Development II Mental or Psychomotor Developmental Indices) by the above 
providers at the age of 2. Neonatal birthweight was classified as AGA (10–90%tile), LGA 
(≥90%tile), or SGA (<10%tile) based upon gender- and gestational-age specific 
contemporary national norms.(18) Secondary outcomes included the components of the 
composite, any CP, and MDI < 85 (one standard deviation below the mean) and PDI <85. 
We also performed a planned subgroup analysis for infants delivered <28 weeks and zero 
days gestation.
Bivariate analyses were performed using chi-square or Fisher’s exact test as appropriate. The 
multivariable analysis was conducted using a stepwise backward-elimination approach for 
all infants, then again in a separate model for those who delivered at <28 weeks and 0 days. 
Covariates were selected for the model based on known associations with the primary 
outcome and those significant in the bivariate analysis. A p- value of <0.05 was considered 
statistically significant. Decision to include magnesium exposure and antenatal 
corticosteroids in the models was made a priori. Covariates with p<0.20 were retained in 
final models. Because of the high concomitant use of MJ and other drugs and tobacco, 
interaction terms were assessed in the final regression model to determine if any of these 
factors were effect modifiers on neonatal or childhood outcomes. A p-value ≤ 0.1 was 
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considered statistically significant. STATA 13.0 (StataCorp, College Station, TX USA) was 
used to perform all analyses.
Results
Of 1867 singleton, non-anomalous preterm infants, 138 (7.2%) were exposed to MJ. MJ-
exposed infants were more likely to be born to mothers who were Black and unmarried 
(Table 1). Compared to those who did not use MJ in pregnancy, those women who used MJ 
during pregnancy were less likely to have received prenatal care and to have graduated high 
school, and were more likely to have used other drugs and smoked cigarettes during 
pregnancy. However, other baseline characteristics (including exposure to antenatal 
corticosteroids or magnesium), did not vary by MJ-exposure.
There were no differences in the frequencies of the composite major neonatal morbidity or 
major childhood morbidity between MJ exposed and non-exposed infants (Table 2). There 
were also no differences in the components of the composite outcomes or other secondary 
outcomes between MJ exposed and non-exposed infants. MJ exposed infants were more 
likely to have a MDI<85 compared to non-exposed infants (p=0.03). When only considering 
infants born at <28 weeks, there was no difference in neonatal or childhood outcomes (Table 
3).
In a multivariable analysis, tobacco and other drugs were not associated with either neonatal 
or childhood outcomes, thus were not retained in the models. For both adverse neonatal and 
early childhood composite outcomes, there was also neither a significant interaction between 
tobacco and MJ use (p=0.64 & 0.68 respectively), nor other drugs and MJ use (p=0.72 & 
p=0.74 respectively). There was a trend toward worse early child outcomes among women 
who used MJ when controlling for covariates (aOR 1.47, 95% CI 0.097, 2.23, p=0.073) 
(Table 4). Interaction was similarly assessed for the subgroup analysis of infants born before 
28 weeks, but once again, no significant interactions were found (all p<0.95). For infants 
born at <28 weeks, MJ use was not associated with increased odds of adverse neonatal or 
early childhood outcomes (Table 5).
Discussion
Among singleton preterm infants born prior to 35 weeks, MJ-exposure in-utero was not 
associated with adverse neonatal or early childhood outcomes, including neonatal death. In 
2015, recreational MJ use was legal in four states, decriminalized and medicinal MJ is 
permitted in several other states and the District of Columbia. Increasingly states are moving 
towards legalization and decriminalization of MJ. In response to any anticipated increase in 
MJ by reproductive age women, publications on MJ-exposure in pregnancy are becoming 
more abundant, though there is still a relative paucity of data on this subject, specifically 
among preterm infants.
Data on neonatal outcomes are limited, and almost entirely relegated to term infants. Most 
recently, Conner et al looked retrospectively at a cohort of approximately 8000 term 
neonates, including 680 who were exposed to MJ.(8) In that cohort, there was no difference 
in adverse neonatal outcomes (including NICU admission, 5 minute Apgar<7, umbilical 
Dotters-Katz et al. Page 4













artery pH<7.1, and birth weight <2500g) among infants exposed to MJ. The same group also 
recently published a meta-analysis to evaluate the effects of MJ-exposure on neonatal 
outcomes, and did not find an association between MJ use and short-term outcomes after 
adjusting for confounding factors.(19)
Day et al studied childhood neurodevelopmental outcomes based on in-utero MJ-exposure at 
three, six, and ten years of age in a high-risk low income population and identified no 
difference at age three in intelligence testing, some decreased verbal reasoning at age 6, and 
worse reading and spelling testing scores at age ten in MJ exposed children compared to 
non-exposed children.(14, 20) In another cohort of children, Fried and colleagues found a 
negative effect of prenatal MJ-exposure on cognition and executive function at age 3, 4, and 
6.(11, 12) Both of these studies had no or very small numbers of preterm infants. Our study 
suggests that neonatal outcomes of preterm infants exposed to MJ prenatally are not 
different than unexposed infants. However, there is a trend in both of our multivariable 
models to an association with adverse childhood outcomes. It may be that follow-up limited 
to two years of age is not long enough to see deficits in higher cognitive functioning 
observed in other longitudinal studies, or simply that we need a larger sample size.
This study has several strengths. First, the data were from a large prospective randomized 
controlled trial, in which data on patients and outcomes were collected using standardized 
protocols by trained research staff. Specifically, childhood neurodevelopmental outcomes 
were collected by trained pediatricians or pediatric neurologists. Of the 1,867 infants in our 
study, 96% were assessed for CP, however only 81% had MDI and PDI testing completed. 
Additionally, data from this study were collected at 20 centers across the United States and 
represent an ethnic makeup similar to the general population, thus making these findings 
more generalizable.
A limitation of this study includes inability to assess the frequency or timing of MJ use 
during pregnancy. Because this is a dichotomous variable in our study, women who used 
daily are categorized the same as those who used once during pregnancy. Though data does 
not exist on MJ specifically regarding quantity of exposure, there is evidence that quantity of 
tobacco or cocaine used is proportionally related to adverse outcomes.(21, 22) At this time, 
there are no human data regarding the fetal effects of MJ based on trimester of exposure. 
Further, we did not have urine drug screen results on all women, and use may be under-
reported. Finally, the majority of babies in this study were delivered following PPROM, an 
obstetric complication traditionally associated with high rates of neonatal and childhood 
morbidity and mortality due to an increased likelihood of infectious morbidity. It is unclear 
whether a similar null-effect of MJ on neonatal and childhood outcomes would be observed 
in a cohort of babies delivered preterm for maternal indications such as preeclampsia, for 
example. In addition, our cohort may have been too small to detect a smaller but potentially 
clinically meaningful difference in neonatal and childhood outcomes between groups. In 
order to detect the observed difference in adverse childhood outcomes of 4.6%, we would 
need over 6500 women, of which 604 used MJ.
In conclusion, among preterm neonates born at <35 weeks largely due to PPROM, in-utero 
exposure to MJ was not associated with an increased risk of adverse neonatal or early 
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childhood developmental outcomes. However the potential trend towards an association with 
adverse childhood outcomes warrants further investigation in a larger cohort with 
quantification of the timing and duration of exposure.
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Table 1
Maternal, delivery, and neonatal characteristics by prenatal marijuana exposure
No Marijuana n=1732 Marijuana n= 135 p value
Maternal characteristics
Age (median, IQR) 26 (21,30) 26 (22,31) 0.33
Race/ethnicity, n (%) <0.001
 Black 741 (42.8) 91 (67.4)
 White 629 (36.3) 38 (28.2)
 Other 362 (20.9) 6 (4.4)
High school or less 1231 (71.1) 111 (82.2) 0.006
Missing 4 (0.2) 0 (0)
Married 849 (49.2) 32 (23.7) <0.0001
Missing 5 (0.3) 0 (0)
Obese (BMI>30) 387 (22.3) 23 (17.0) 0.07
Missing 197 (11.4) 8 (5.9)
Multiparous 1115 (64.5) 89 (65.9) 0.72
Prior PTB 484 (27.9) 36 (26.7) 0.75
Smoking 431 (24.9) 104 (77.0) <0.0001
Other drugs 58 (3.4) 43 (31.9) <0.0001
Diabetes 91 (5.3) 5 (3.7) 0.43
Chronic medical conditions (HTN) 304 (17.6) 17 (12.6) 0.14
Delivery characteristics
No prenatal care 123 (7.1) 23 (17.4) <0.0001
Any magnesium exposure 1010 (58.4) 86 (63.7) 0.22
Corticosteroids 1683 (97.2) 131 (97.0) 0.93
PPROM 1519 (87.7) 123 (91.1) 0.24
Cesarean delivery 647 (37.4) 39 (28.9) 0.05
Neonatal characteristics
Gestational age (wks) 29 (27, 32) 30 (28, 31) 0.41
Preterm < 28 wks 534 (30.8) 35 (25.9) 0.23
Birth weight (grams) 1355 (981,1722) 1360 (1075,1640) 0.88
Male infant 931 (53.8) 68 (50.4) 0.45
Five-minute Apgar < 7 318 (18.4) 22 (16.3) 0.54
Missing 3 (0.2) 0 (0)
Abbreviations: IQR, interquartile range; BMI, body mass index; PTB, preterm birth; HTN, hypertension; PPROM, preterm premature rupture of 
membranes
Values are n(%),median (interquartile range)
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Table 2
Neonatal outcomes by prenatal marijuana exposure
No Marijuana n=1732 Marijuana n= 135 p value
Adverse neonatal outcome* 477 (25.8) 27 (20.0) 0.14
 Death before hospital discharge 92 (5.3) 5 (3.7) 0.43
 Missing 9 (0.5) 2 (1.5)
 Severe NEC 82 (4.7) 7 (5.2) 0.79
   Missing 9 (0.5) 2 (1.5)
 Grade 3 or 4 IVH 35 (2.0) 1 (0.8) 0.28
Missing 78 (4.5) 1 (0.7)
 Bronchopulmonary dysplasia 313 (18.1) 16 (11.8) 0.07
Missing 9 (0.5) 2 (1.5)
Periventricular leukomalacia 35 (2.0) 2 (1.5) 0.63
Missing 78 (4.5) 1 (0.7)
Adverse early childhood outcome** 369 (21.3) 35 (25.9) 0.21
 Death prior to age 2 28 (1.6) 3 (2.2) 0.60
 Moderate or severe cerebral palsy 38 (2.2) 0 (0) 0.08
   Missing 77 (4.5) 3 (2.2)
 MDI<70 235 (13.6) 25 (18.5) 0.12
   Missing 339 (19.6) 25 (18.5)
 PDI <70 209 (12.1) 20 (14.8)
0.35
   Missing 326 (18.8) 25 (18.5)
Other outcomes
Intrauterine growth restriction 69 (4.0) 4 (3.0) 0.56
Small for gestational age ^ (<10th percentile) 41 (2.4) 4 (3.0) 0.66
Large for gestational age ^ (≥90th percentile) 215 (12.4) 12 (8.9) 0.23
Any cerebral palsy 77 (4.5) 3 (2.2)
0.20
   Missing 77 (4.5) 3 (2.2)
MDI<85 610 (35.2) 60 (44.4)
0.03
   Missing 339 (19.6) 25 (18.5)
PDI <85 464 (33.5 39 (28.9)
0.60
   Missing 326 (18.8) 25 (18.5)
P value denotes association between marijuana exposure and variable using chi-square or Kruskal Wallis test, as appropriate.
Abbreviations: NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage, PVL, periventricular leukomalacia; BPD, bronchopulmonary 
dysplasia; MDI, mental developmental indices; PDI, psychomotor developmental indices
*
Composite Primary Short term outcome: Death, Grade 3 or 4 IVH, PVL, NEC, BPD
**
Composite Primary Long term Outcome: Death before age 2, moderate or severe cerebral palsy, PDI or MDI <70
^
by sex and gestational age at delivery for US population
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Table 3
Neonatal outcomes by prenatal marijuana exposure for women who delivered at <28 weeks (n=569)
No Marijuana n=534 Marijuana n=35 p-value
Adverse neonatal outcome* 336 (62.8) 19 (54.3) 0.37
 Death before hospital discharge 73 (13.7) 4 (11.4) >0.99
 Missing 6 (1.1) 0
 Severe NEC 43 (8.0) 4 (11.1) 0.52
   Missing 6 (1.1) 0
 Grade 3 or 4 IVH 27 (4.9) 1 (3.6) >0.99
Missing 33 (6.2) 0
 BPD 260 (48.7) 13 (37.1) >0.99
Missing 6 (1.1) 0
PVL 18 (3.5) 1 (2.8) >0.99
Missing 38 (6.9) 0
Adverse early childhood outcome** 167 (31.3) 15 (42.9) 0.19
 Death prior to age 2 14 (2.6) 1 (2.8) >0.99
 Moderate or severe cerebral palsy 23 (4.3) 0 0.39
   Missing 17 (3.2) 1 (2.9)
 MDI <70 107 (20.0) 10 (28.6) 0.25
   Missing 147 (27.5) 10 (28.6)
 PDI <70 99 (18.6) 9 (25.7) 0.24
   Missing 138 (25.8) 10 (28.6)
Other outcomes
Intrauterine growth restriction 34 (6.4) 1 (2.9) 0.72
Small for gestational age ^ (<10th percentile) 10 (1.9) 0 >0.99
Large for gestational age ^ (≥90th percentile) 51 (9.6) 1 (2.9) 0.24
Any cerebral palsy 54 (9.8) 1 (1.8) 0.24
   Missing 19 (3.5) 1 (2.8)
MDI<85 219 (41.0) 18 (51.4) 0.15
   Missing 147 (27.5) 10 (28.6)
PDI <85 182 (34.1) 15 (42.9) 0.22
   Missing 138 (25.8) 10 (228.6)
Abbreviations: NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage, PVL, periventricular leukomalacia; BPD, bronchopulmonary 
dysplasia; MDI, mental developmental indices; PDI, psychomotor developmental indices
P value denotes association between marijuana exposure and variable using Fisher’s exact test
*
Composite Primary Short term outcome: Death, Grade 3 or 4 IVH, PVL, NEC, BPD
**
Composite Primary Long term Outcome: Death before age 2, moderate or severe cerebral palsy, PDI or MDI <70
^
by sex and gestational age at delivery for US population
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Table 4
Multivariable logistic regression model. Shown are factors associated with neonatal morbiditya (n=1866) and 
childhood morbidityb (n=1862).
Characteristics associated with neonatal morbidity OR 95% CI p-value
Marijuana use 0.83 0.47, 1.44 0.50
Race (African American = referent) – – –
 Caucasian 1.34 0.98, 1.81 0.064
   Other 0.62 0.42, 0.92 0.018
No prenatal care 0.51 0.29, 0.89 0.018
Received magnesium sulfate 1.04 0.79, 1.38 0.76
Male infant 1.68 1.27, 2.21 <0.01
PPROM 0.59 0.40, 0.88 0.010
Received steroids 1.04 0.46, 2.38 0.92
Gestational age at delivery (additional week) 0.48 0.45, 0.52 <0.01
Delivery route – Cesarean 1.48 1.12, 1.95 <0.01
Characteristics associated with childhood morbidity OR 95% CI p-value
Marijuana use 1.47 0.97, 2.23 0.073
Race (African American = referent) – – –
 Caucasian 0.90 0.69, 1.17 0.42
   Other 1.27 0.94, 1.72 0.12
No prenatal care 0.73 0.47, 1.15 0.17
Received magnesium sulfate 0.96 0.76, 1.21 0.75
High school education or less 1.23 0.94, 1.60 0.13
Male infant 1.50 1.19, 1.88 <0.01
Received steroids 0.96 0.49, 1.88 0.90
Gestational age at delivery (each additional week) 0.85 0.81, 0.89 <0.01
Delivery route – Cesarean 1.21 0.97, 1.54 0.094
a
Additional factors considered in the model: Recreational drug use, tobacco use, marital status, high school education or less
b
Additional factors considered in the model: Recreational drug use, tobacco use, marital status, and preterm premature rupture of membranes
Abbreviations: PPROM, preterm premature rupture of membranes;
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Table 5
Multivariable logistic regression model. Shown are factors associated with neonatal morbiditya (n=567) and 
childhood morbidityb (n=569) in infants born at <28 weeks
Characteristics associated with neonatal morbidity OR 95% CI p-value
Marijuana use 0.84 0.39, 1.85 0.67
Race (African American = referent) – – –
 Caucasian 1.17 0.75, 1.81 0.49
   Other 0.58 0.35, 0.97 0.036
No prenatal care 0.58 0.28, 1.20 0.14
High school education or less 0.58 0.37, 0.90 0.016
Received magnesium sulfate 1.00 0.68, 1.47 <0.99
Male infant 1.68 1.15, 2.46 0.007
PPROM 0.55 0.30, 1.00 0.051
Received steroids 0.51 0.17, 1.51 0.23
Gestational age at delivery (each additional week) 0.44 0.36, 0.54 <0.01
Delivery route – Cesarean 1.40 0.95, 2.06 0.085
Characteristics associated with childhood morbidity OR 95% CI p-value
Marijuana use 1.73 0.86, 3.50 0.13
Received magnesium sulfate 0.92 0.64,1.32 0.67
Male infant 1.34 0.94, 1.92 0.11
Received steroids 2.22 0.63, 7.83 0.22
Gestational age at delivery (each additional week) 0.81 0.68, 0.96 0.014
a
Additional factors considered in the model: Recreational drug use, tobacco use, marital status, no prenatal care
b
Additional factors considered in the model: Race, recreational drug use, tobacco use, marital status, no prenatal care, high school education or 
less, preterm premature rupture of membranes, and mode of delivery
Abbreviations: PPROM, preterm premature rupture of membranes
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